Evaluation of the Risk of Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus

The goal of this study, performed entirely with computer programs, is to learn if using a combination of two drugs works better than using one alone, in the treatment of people with chronic kidney disease and type 2 diabetes mellitus. The main questions it aims to answer are: * How many events of heart failure, heart failure hospitalizations, and cardiovascular death happen in each group? * How do serious kidney problems progress in each of the groups? Researchers will compare reference therapy (finerenone) with a combination of finerenone and empagliflozin. There will not be human participants in this study. With the help of artificial intelligence, researchers will recreate a large population of people with chronic kidney disease and type 2 diabetes mellitus. Data on their disease, treatment, and laboratory parameters will be based on and simulated using real data from previous clinical trials conducted with real participants.

Inclusion Criteria: The same characteristics of the reference population: CONFIDENCE trial (NCT05254002). In brief: * Patients with chronic kidney disease (eGFR 30-90 ml/min/1.73 m²) * Persistent albuminuria (UACR 100-5000 mg/g) * Type 2 diabetes mellitus (T2D) under stable blockade of the renin-angiotensin system (ACEi/ARB) Exclusion Criteria: The same characteristics of the reference population: CONFIDENCE trial (NCT05254002). In brief: * Participants with type 1 diabetes (T1D). * Participant with hepatic insufficiency classified as Child-Pugh C. * Participants currently treated or who were treated with Finerenone (Kerendia©) within 8 weeks prior to the screening visit.